Prinelli F, Adorni F, Giovanelli A, Ravelli M, Ceresoli S, Asteria C
Epidemiology and Public Health Unit, Institute of Biomedical Technologies, National Research Council, Via Fratelli Cervi 93, 20054, Segrate, MI, Italy.
National Institute of Obesity Cure (INCO)-Bariatric Unit, IRCCS, Policlinico San Donato, Piazza Edmondo Malan, 2, San Donato Milanese, 20097, Milan, Italy.
J Endocrinol Invest. 2025 Jan;48(1):173-189. doi: 10.1007/s40618-024-02407-1. Epub 2024 Jun 10.
To assess the occurrence and severity of SARS-CoV-2 infection/COVID-19, frequency of symptoms, clinical manifestations and behaviours in a sample of patients undergoing bariatric surgery (BS).
The EPICOVID19-BS is an observational cross-sectional study conducted in Italy during the second wave of the COVID-19 pandemic (September 2021-February 2022). Patients with severe/extreme obesity undergoing BS were asked to complete an online multiple-choice questionnaire and to provide additional clinical information and blood biochemistry. Positive COVID-19 cases were defined by the combination of positive nasopharyngeal swab test results and/or positive serological test results. Sociodemographic, clinical and behavioural characteristics were compared between positive and negative COVID-19 cases.
A total of 745 participants were enrolled (mean age 44.5 ± 10.5 years SD, 78% female). The proportion of positive COVID-19 cases was 20.4%. They were more likely to be health care workers, to have close contacts with confirmed cases, to use anti-inflammatory drugs, to have immune system disorders, to have previous CMV infection, to have lower cholesterol levels and to have less metabolic syndrome than negative cases. Infected participants significantly increased their use of national health resources for minor health problems. The majority of participants experienced flu-like symptoms and taste and smell disturbances. Only 9.6% were hospitalised and none required intubation.
Our results seem to support the evidence that patients undergoing BS have a low rate of severe SARS-CoV2. Further longitudinal studies in multiple obesity treatment centres are needed to more effectively monitor and control obesity in this specific population.
评估接受减肥手术(BS)的患者样本中SARS-CoV-2感染/新冠肺炎的发生率和严重程度、症状频率、临床表现及行为。
EPICOVID19-BS是在意大利新冠肺炎疫情第二波期间(2021年9月至2022年2月)进行的一项观察性横断面研究。要求接受BS的重度/极度肥胖患者完成一份在线多项选择题问卷,并提供额外的临床信息和血液生化指标。新冠肺炎阳性病例由鼻咽拭子检测结果阳性和/或血清学检测结果阳性共同确定。比较新冠肺炎阳性和阴性病例的社会人口统计学、临床和行为特征。
共纳入745名参与者(平均年龄44.5±10.5岁,标准差,78%为女性)。新冠肺炎阳性病例的比例为20.4%。与阴性病例相比,他们更有可能是医护人员,与确诊病例有密切接触,使用抗炎药物,有免疫系统疾病,既往有巨细胞病毒感染,胆固醇水平较低,代谢综合征较少。受感染的参与者因轻微健康问题显著增加了对国家卫生资源的使用。大多数参与者出现流感样症状以及味觉和嗅觉障碍。只有9.6%的人住院,无人需要插管。
我们的结果似乎支持了接受BS的患者严重感染SARS-CoV-2的比率较低这一证据。需要在多个肥胖治疗中心进行进一步的纵向研究以更有效地监测和控制这一特定人群的肥胖情况。